The Mission of the Ontario Rheumatology Association is to represent Ontario Rheumatologists and promote their pursuit of excellence in Arthritis care in Ontario through Leadership, Advocacy, Education and Communications.
  • ORA 14th Annual Meeting

    The ORA 2015 Annual Meeting is being held May 22-24, 2015. 

Recent News

  • Methotrexate injectable availability

    Methotrexate 50mg/2mL with Preservative Vials - Sandoz vs Mayne Brand
    The Sandoz product, DIN#02398427, is now the only product reimbursed by the Ontario Drug Benefit program at a cost of $8.92.

    The previous product and still available alternative product by Mayne, DIN#02182777 will not be provided to ODB recipients because it is a higher cost ($12.48) and the ODB program will only reimburse the pharmacy $8.92 per vial.

    Removing the plastic wrap/seal on the Sandoz product creates a challenge for many patients with arthritis.  In some cases the density of the rubber seal on the Sandoz vial has caused the needles (29 or 30 gauge) on insulin syringes used to self-administer the medication subcutaneously to bend.

    Personal communications between a pharmacist from The Arthritis Program at Southlake Regional Health Centre and a Sandoz company representative in August 2014 indicated that the company was aware of these challenges with their product’s packaging and the pharmacist was informed that a revised packaging should be available/released at the end of October 2014.

  • ORA launches new website Rheumcareers

    The ORA has launched Rheumcareers, a new website to increase rheumatology visibility to medical students/PGY1 and 2 as well as serving as a tool to help rheumatology residents find employment once their training is complete. Visit the website here!

  • New Diclofenac dosages and warnings from Health Canada

    Diclofenac - Update to Heart and Stroke Related Safety Information and Decrease in the Maximum Recommended Daily Dose for Tablets and Suppositories - Novartis Pharma Canada Inc. and Pfizer Canada Inc.

    Diclofenac at 150 mg per day, is associated with an increased risk of serious cardiovascular adverse events. The maximum recommended daily dose of systemic diclofenac is now 100 mg per day. Diclofenac is not recommended in patients with pre-existing cardiovascular or cerebrovascular disease.

  • View All News

Upcoming Events for 2014

  • The Arthritis Society’s Jewels and Jeans Gala
    November 8, 2014, Burlington Golf & Country Club

    We would love to have the presence of the Rheumatologists, colleagues, family and friends on behalf of the people the Rheumatologists serve….people living with arthritis.  It’s an opportunity for all of us to gather for an evening of fun with old and new friends, honouring those we serve and raise funds for research in pursuit of helping those affected with arthritis to live better lives and provide them with the tools, education, programs and services they need.

  • EMR User Forum 2015
    January 15, 2015, Sheraton Gateway Airport Hotel (Toronto International Airport - Terminal 3)

    Learn about new EMR tools and OntarioMD updates. Deliver better patient care and maximize your office efficiency! Register today!

  • View All Events

Corporate Sponsors

Diamond: The Arthritis Society, Pfizer Canada Inc., Amgen Canada Inc., Janssen Inc., Celgene Inc., Bristol-Myers Squibb Canada, Roche Canada
Platinum: GlaxoSmithKline Inc., UCB Canada Inc., AstraZeneca Canada Inc., Abbvie., Takeda Canada Inc.